Hemostasis products market seen reaching $2.52 billion by 2030

The hemostasis products market is projected to grow from $1.8 billion in 2025 to $1.91 billion in 2026, then climb to $2.52 billion by 2030, according to The Business Research Company. Rising cardiac disorders, more surgeries and trauma cases, and broader use of advanced clotting technologies are driving demand.

Why it matters: - Hemostasis products are used to control bleeding and support clot formation during surgery, trauma care and wound healing. - Rising demand matters because hospitals and clinicians are trying to cut bleeding complications, lower transfusion needs and improve patient outcomes. - The market’s projected rise to $2.52 billion by 2030 signals sustained demand for products that support faster bleeding control.

What happened: - The Business Research Company released a report on the global hemostasis products market covering 2026 through 2035. - The market is projected to grow from $1.8 billion in 2025 to $1.91 billion in 2026. - The report forecasts the market will reach $2.52 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region in the coming years.

The details: - The report links recent growth to more surgical operations, more trauma incidents, higher prevalence of bleeding disorders and expanded hospital surgical capacity. - The forecast through 2030 reflects a 7.2% CAGR. - The 2026 step-up from 2025 reflects a 6.1% CAGR. - Growth is expected to come from broader use of advanced biological and synthetic agents. - Demand is also being supported by minimally invasive surgical techniques, trauma care infrastructure and a stronger focus on faster wound healing. - The report highlights broader adoption of sophisticated hemostatic agents, more topical and sealant-based products, and greater use in surgery and trauma care. - The report also points to stronger demand for biocompatible materials. - The source says hemostasis products include medical substances and devices designed to control bleeding and promote clot formation in clinical settings. - The report says the market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics and updated graphics. - Download a free sample of the report. - View the full market report.

Between the lines: - Cardiac disorders are a key demand driver because bleeding complications can arise during heart-related treatments. - The report cites an American Heart Association update from January 2024 showing the U.S. age-adjusted cardiovascular death rate rose to 233.3 per 100,000 from 224.4 per 100,000 in 2023. - That increase underscores a larger burden of cardiovascular disease, which can translate into more need for hemostatic products. - The emphasis on minimally invasive procedures suggests manufacturers may keep shifting toward products that work quickly and reliably in smaller surgical environments.

What's next: - The market is expected to keep expanding as hospitals, trauma centers and surgical teams prioritize faster bleeding control. - Product development is likely to focus on advanced clotting technologies, sealant-based solutions and materials that are more biocompatible. - Asia-Pacific’s rapid growth could make the region a bigger strategic target for suppliers and distributors.

The bottom line: - Hemostasis products are moving from a specialized category to a larger growth market, powered by more surgery, more trauma care and rising cardiovascular disease.